XBIO
Income statement / Annual
Last year (2024), Xenetic Biosciences, Inc.'s total revenue was $2.50 M,
a decrease of 1.56% from the previous year.
In 2024, Xenetic Biosciences, Inc.'s net income was -$3.96 M.
See Xenetic Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$2.50 M |
$2.54 M |
$1.71 M |
$1.16 M |
$436.94 K |
$17.07 K |
$0.00 |
$7.59 M |
$3.00 M |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$15.83 K
|
$156.12 K
|
$36.45 K
|
$56.12 K
|
| Gross Profit |
$2.50 M
|
$2.54 M
|
$1.71 M
|
$1.16 M
|
$436.94 K
|
$17.07 K
|
-$15.83 K
|
$7.43 M
|
$2.96 M
|
-$56.12 K
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0.98
|
0.99
|
0
|
| Research and Development Expenses |
$3.29 M
|
$3.49 M
|
$4.77 M
|
$3.16 M
|
$1.73 M
|
$4.89 M
|
$2.88 M
|
$4.06 M
|
$43.74 M
|
$3.43 M
|
| General & Administrative Expenses |
$3.42 M
|
$3.56 M
|
$3.65 M
|
$3.74 M
|
$3.40 M
|
$4.73 M
|
$4.39 M
|
$6.94 M
|
$6.69 M
|
$6.39 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.42 M
|
$3.56 M
|
$3.65 M
|
$3.74 M
|
$3.40 M
|
$4.73 M
|
$4.39 M
|
$6.94 M
|
$6.69 M
|
$6.39 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9.24 M
|
$3.28 M
|
-$24.64 K
|
-$41.10 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$6.70 M
|
$7.06 M
|
$8.42 M
|
$6.91 M
|
$14.37 M
|
$12.90 M
|
$7.28 M
|
$11.00 M
|
$50.43 M
|
$9.82 M
|
| Cost And Expenses |
$6.70 M
|
$7.06 M
|
$8.42 M
|
$6.91 M
|
$14.37 M
|
$12.90 M
|
$7.28 M
|
$11.15 M
|
$50.43 M
|
$9.82 M
|
| Interest Income |
$249.86 K
|
$355.76 K
|
$167.15 K
|
$100.47 K
|
$126.17 K
|
$108.49 K
|
$0.00
|
$16.54 K
|
$32.00
|
$1.69 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$24.13 K
|
$1.82 K
|
$729.57 K
|
$267.00 K
|
| Depreciation & Amortization |
$153.34 K
|
$0.00
|
$27.04 K
|
$35.48 K
|
$28.84 K
|
$27.49 K
|
$15.83 K
|
$23.78 K
|
$36.45 K
|
$56.12 K
|
| EBITDA |
-$4.05 M |
-$4.52 M |
-$6.69 M |
-$5.71 M |
-$4.67 M |
-$9.58 M |
-$7.26 M |
-$3.57 M |
-$53.44 M |
-$9.77 M |
| EBITDA Ratio |
-1.62
|
-1.78
|
-3.92
|
-4.92
|
-10.68
|
-561.11
|
0
|
-0.47
|
-17.81
|
0
|
| Operating Income Ratio |
-1.68
|
-1.78
|
-3.94
|
-4.95
|
-31.9
|
-755.12
|
0
|
-0.47
|
-15.81
|
0
|
| Total Other Income/Expenses Net |
$244.15 K
|
$381.14 K
|
$165.56 K
|
$101.59 K
|
$125.68 K
|
$111.80 K
|
-$24.13 K
|
-$26.37 K
|
-$6.78 M
|
-$2.69 M
|
| Income Before Tax |
-$3.96 M
|
-$4.13 M
|
-$6.55 M
|
-$5.65 M
|
-$13.81 M
|
-$12.78 M
|
-$7.30 M
|
-$3.60 M
|
-$54.21 M
|
-$12.51 M
|
| Income Before Tax Ratio |
-1.58
|
-1.63
|
-3.84
|
-4.86
|
-31.61
|
-748.57
|
0
|
-0.47
|
-18.07
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.92 M
|
$0.00
|
$24.13 K
|
$26.37 K
|
$0.00
|
$0.00
|
| Net Income |
-$3.96 M
|
-$4.13 M
|
-$6.55 M
|
-$5.65 M
|
-$10.89 M
|
-$12.78 M
|
-$7.30 M
|
-$3.60 M
|
-$54.21 M
|
-$12.51 M
|
| Net Income Ratio |
-1.58
|
-1.63
|
-3.84
|
-4.86
|
-24.93
|
-748.57
|
0
|
-0.47
|
-18.07
|
0
|
| EPS |
-2.57 |
-2.71 |
-4.49 |
-5.39 |
-17.04 |
-55.92 |
-96.58 |
-49.78 |
-875.41 |
-355.34 |
| EPS Diluted |
-2.57 |
-2.71 |
-4.49 |
-5.39 |
-17.04 |
-55.92 |
-96.57 |
-49.78 |
-875.41 |
-355.34 |
| Weighted Average Shares Out |
$1.54 M
|
$1.53 M
|
$1.42 M
|
$1.03 M
|
$639.24 K
|
$285.25 K
|
$75.59 K
|
$72.21 K
|
$61.92 K
|
$35.20 K
|
| Weighted Average Shares Out Diluted |
$1.54 M
|
$1.53 M
|
$1.42 M
|
$1.03 M
|
$639.24 K
|
$285.25 K
|
$75.60 K
|
$72.21 K
|
$61.92 K
|
$35.20 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
